Assessment of Safety and Functional Efficacy of Stem Cell-Based Therapeutic Approaches Using Retinal Degenerative Animal Models

Figure 5

Genotyping assays of immunodeficient S334ter-3 rats. (a) S334ter transgene genotyping assay. Lane 1 15 bp–3 kb size marker. Lane 2 transgene-negative sample. Lane 3 transgene-positive sample. Sizes in base pairs (bp) are indicated to the left of the image. An amplicon of 350 bp indicates the presence of the transgene. The 15- and 3000-bp alignment markers are present in all lanes. (b) Allelic discrimination assay plot for detection of the Foxn1rnu mutation. The fluorescence levels of VIC (wild type, allele X) and FAM (mutant, allele Y) are plotted on the x-axis and y-axis, respectively. The genotypes of each sample are represented by blue diamonds (homozygous Foxn1rnu), red circles (homozygous for the wild-type Foxn1 allele), or green triangles (heterozygous +/Foxn1rnu). The no template negative control is represented by the gray box. Reprinted from Graefes Arch Clin Exp Ophthalmol, vol. 252, Seiler et al., a new immunodeficient pigmented retinal degenerate rat strain to study transplantation of human cells without immunosuppression, pages 1079–1092, copyright (2014), with permission from Elsevier. DOI 10.1007/s00417-014-2638-y.

(a)

(b)